Results 31 to 40 of about 70,073 (274)

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

New England Journal of Medicine, 2020
BACKGROUND We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had ...
M. Hussain, J. Mateo, K. Fizazi, F. Saad, N. Shore, S. Sandhu, K. Chi, O. Sartor, N. Agarwal, D. Olmos, A. Thiery-Vuillemin, P. Twardowski, G. Roubaud, M. Özgüroğlu, Jinyu Kang, J. Burgents, C. Gresty, C. Corcoran, C. Adelman, J. D. de Bono   +19 more
semanticscholar   +1 more source

Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.

European Urology, 2022
BACKGROUND Hormonal therapy targeting the androgen receptor inhibits prostate cancer (PCa), but the tumor eventually recurs as castration-resistant prostate cancer (CRPC).
Q. Cheng, W. Butler, Yinglu Zhou, Hong Zhang, Lu Tang, Kathryn R. Perkinson, Xufeng Chen, X. Jiang, S. McCall, B. Inman, Jiaoti Huang   +10 more
semanticscholar   +1 more source

Autocrine activation of MAPK signaling mediates intrinsic tolerance to androgen deprivation in LY6D prostate cancer cells

Cell Reports, 2023
Summary: The emergence of castration-resistant prostate cancer remains an area of unmet clinical need. We recently identified a subpopulation of normal prostate progenitor cells, characterized by an intrinsic resistance to androgen deprivation and ...
Ivana Steiner, Teresita del N.J. Flores-Tellez, Renaud Mevel, Amin Ali, Pengbo Wang, Pieta Schofield, Caron Behan, Nicholas Forsythe, Garry Ashton, Catherine Taylor, Ian G. Mills, Pedro Oliveira, Simon S. McDade, Dietmar M. Zaiss, Ananya Choudhury, Georges Lacaud, Esther Baena   +16 more
doaj   +1 more source

Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen. [PDF]

PLoS ONE, 2012
As prostate cancer progresses to castration-resistant disease, there is an increase in signal transduction activity. Most castration-resistant prostate tumors continue to express the androgen receptor (AR) as well as androgen-responsive genes, despite ...
Hilary Whitworth, Shriti Bhadel, Melissa Ivey, Mark Conaway, Andrea Spencer, Ronald Hernan, Heather Holemon, Daniel Gioeli   +7 more
doaj   +1 more source

Knowledge mapping of immunotherapy in castration-resistant prostate cancer: a bibliometric and visualized study (2003–2022)

Frontiers in Urology, 2023
ObjectiveTo utilize bibliometric analysis to examine the literature about immunotherapy for castration-resistant prostate cancer published within the past two decades.
Xianfu Cai, Xianfu Cai, Chenguang Ding, Yang Li, Jin Zheng, Wujun Xue   +5 more
doaj   +1 more source

Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer

New England Journal of Medicine, 2018
BACKGROUND Men with nonmetastatic, castration‐resistant prostate cancer and a rapidly rising prostate‐specific antigen (PSA) level are at high risk for metastasis.
M. Hussain, K. Fizazi, F. Saad, P. Rathenborg, N. Shore, U. Ferreira, P. Ivashchenko, E. Demirhan, K. Modelska, D. Phung, A. Krivoshik, C. Sternberg   +11 more
semanticscholar   +1 more source

Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer

Cell Reports, 2018
Summary: The exact identity of castrate-resistant (CR) cells and their relation to CR prostate cancer (CRPC) is unresolved. We use single-cell gene profiling to analyze the molecular heterogeneity in basal and luminal compartments.
João D. Barros-Silva, Douglas E. Linn, Ivana Steiner, Guoji Guo, Adnan Ali, Hubert Pakula, Garry Ashton, Isabel Peset, Michael Brown, Noel W. Clarke, Roderick T. Bronson, Guo-Cheng Yuan, Stuart H. Orkin, Zhe Li, Esther Baena   +14 more
doaj   +1 more source

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

Journal of Clinical Oncology, 2020
PURPOSE BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors.
W. Abida, Akash Patnaik, D. Campbell, J. Shapiro, A. Bryce, R. McDermott, B. Sautois, N. Vogelzang, R. Bambury, E. Voog, Jingsong Zhang, J. Piulats, C. Ryan, A. Merseburger, G. Daugaard, A. Heidenreich, K. Fizazi, C. Higano, L. Krieger, C. Sternberg, S. Watkins, D. Despain, A. Simmons, A. Loehr, Melanie Dowson, Tony Golsorkhi, S. Chowdhury   +26 more
semanticscholar   +1 more source

Managing Nonmetastatic Castration-resistant Prostate Cancer

European Urology, 2019
Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have rising prostate-specific antigen (PSA) and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan. Given recent drug approvals for nmCRPC, with many other therapeutics and imaging modalities being developed ...
Mateo, J, Fizazi, K, Gillessen, S, Heidenreich, A, Perez-Lopez, R, Oyen, WJG, Shore, N, Smith, M, Sweeney, C, Tombal, B, Tomlins, SA, de Bono, JS   +11 more
openaire   +4 more sources

Gene Expression Profiling Analysis Reveals Putative Phytochemotherapeutic Target for Castration-Resistant Prostate Cancer

Frontiers in Oncology, 2019
Prostate cancer is the leading cause of cancer death among men globally, with castration development resistant contributing significantly to treatment failure and death.
Solomon Oladapo Rotimi, Oluwakemi Anuoluwapo Rotimi, Abdulkadir Ayo Salako, Paul Jibrin, Jelili Oyelade, Emeka E. J. Iweala   +5 more
doaj   +1 more source